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1. Introduction 
Grafting of neural stem cells into the mammalian central nervous system (CNS) has been 
performed for some decades now, both in basic research and clinical applications for 
neurological disorders such as Parkinson's and Huntington's disease, stroke, and spinal cord 
injuries. Albeit the “proof of principle” status that neural grafts can reinstate functional 
deficits and rebuild damaged neuronal circuitries, many critical roadblocks have still to be 
overcome to reach clinical applications. Among these are the manifold immunological 
aspects that are encountered during the graft–host interaction in vivo. In this chapter we 
will elucidate different aspects of cellular therapy, particularly using CNS derived stem cells 
and their ability to modulate immune system in order to avoid rejection and/or affect 
inflammatory reactions related to neurodegenerative diseases. 
2. Neural transplantation for the therapy of neurodegenerative diseases 
2.1 NSCs: Use into humans and animal models 
Grafting of neural stem cells (NSCs) into the mammalian central nervous system in association 
with their ability to induce  active neurogenesis in the adult CNS has fostered a flurry of 
studies to investigate the exploitation of NSC for the therapy of neurodegenerative disorders 
including both genetic diseases like Metachromatic Leukodystrophy (MLD), Huntington’s 
Disease (HD), Alzheimer’s Disease (AD) (sporadic) and idiopathic diseases like Parkinson’s 
Disease (PD), AD, Multiple Sclerosis (MS), Amyotrophyc Lateral Sclerosis (ALS), stroke. 
Regenerative medicine strongly relies on the capacity of intrinsic subsets of cells to replenish 
the damaged ones. Although for a long time the CNS was thought to be a “perennial”, i.e. 
post-mitotic tissue, the discovery of active neurogenesis in the adult mammalian brain has 
debunked this dogma and spurred ongoing research efforts to focus on stem/ precursor cell 
therapy to treat neurodegeneration and neurotrauma.  
Given the intrinsic resilience of NSC to fast proliferation and prompt expansion in vivo, the 
spontaneous recovery of most CNS injuries remains limited and a feasible strategy to 
support the endogenous NSC-mediated therapy would be the autologous transplantation of 
adult stem cells from various tissue compartments than the CNS. Different sources of stem 
cells have been proposed, but they mostly generate a restricted range of cell phenotypes.  
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Induced pluripotent stem cells (iPS) have been recently proposed for autologous 
transplantation, but a major drawback of these genetically manipulated cells is the high risk 
of cancer formation, mainly due to the uncontrolled integration of retroviral vectors and 
recombination events.  
Therefore, the most feasible candidates to clinical neurological  applications are currently 
the embryonic stem cells (ESCs) and adult somatic stem cells,  particularly NSCs.  
ESCs are the most primitive type of stem cells properly belonging to the human body and 
are pluripotent, meaning that they are able to generate all the types of cells present in the 
human body. As such and thanks to their easy handling and proliferation ex vivo, they 
would represent ideal candidates to provide a wide array of cell types for the therapy of 
different disorders. Alas, the limited availability of primary tissue due to ethical concerns 
and their remarkable teratogenic potential in vivo has strongly discouraged their application 
in clinical trials. On the contrary, NSC are mostly considered as the optimal cell type for cell-
mediated therapy of neural disorders because they share the same tissue origin of the 
damaged cells they are meant to replenish and are amenable to local environmental cues 
able to commit their differentiation choice (Cao et al. 2001;Shihabuddin et al. 2000;Suhonen 
et al. 1996). Accordingly, NSC have been shown to exert multiple therapeutic effects, such as 
secretion of neurotrophic factors and cytokines, scavenging of toxic molecules, 
immunomodulation of inflammatory milieu, where neural cell replacement plays only a 
minor role in the recovery of CNS damage (Bacigaluppi et al. 2009;Behrstock et al. 
2006;Ebert et al. 2008;Lindvall and Kokaia 2010). The major roadblock to their procurement 
from an autologous tissue source can be currently circumvented by their derivation from the 
fetal human brain, while the requirement for immunosuppression to prevent transplant 
rejection remains object of conflicting debates. 
Above all the disavantages of using immunosuppressive treatment during stem cells 
therapies include an increased risk for opportunistic infections (Garrido et al. 2006), toxic 
side effects (Rezzani 2006) and potential negative effects on donor cells as recently described 
(Guo et al. 2007) for cyclosporin treatment able to reduce cell proliferation and affect 
differentiation of rat NSCs in vitro. 
In this manuscript we will discuss about NSC immunogenic potential and the exploitation 
of –mild- and/or transient immune suppressive protocols after NSC transplantation. 
3. Neural stem cells 
Somatic adult NSCs are undifferentiated cells that reside in specialized regions, namely the 
niche, of the fetal and adult CNS; they possess life-long self-renewal ability and a 
multipotent differentiation potential, given their ability to generate neurons, astrocytes and 
oligodendrocytes. Reynolds and Weiss (Reynolds and Weiss 1992) have first demonstrated a 
stem cell niche in the CNS. In particular, the finding of adult neurogenesis in the SVZ, which 
leads to the generation of neural progenitors migrating to the olfactory bulbs and to the 
cortex, has favoured the idea that newborn neurons might subserve cognitive functions and 
contribute to the homeostasis of the telencephalic-diencephalic area.  
Therefore, NSCs maintain the functional and structural integrity of the brain in 
physiological conditions, thus contributing to tissue homeostasis and repair throughout 
adulthood (Gage et al. 1998;Reynolds and Weiss 1992;Temple and Alvarez-Buylla 1999). 
Alas, given the inherent resilience of NSC to rapidly expand into the adult CNS, there is 
limited spontaneous recovery after brain damage (Popa-Wagner et al. 2009;Romanko et al. 
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2004), so the integration of new functional neurons following injury can be achieved by 
transplanting exogenous cells. In vitro, NSCs can be propagated as free-floating aggregates 
called neurospheres or as a cell monolayer (on adhesion) and demonstrate the same 
characteristics of self-renewal and potential to differentiate into functionally mature neural 
cells. The establishment of protocols to isolate and culture NSC as stable cell lines able to 
maintain unaltered their functional properties over passaging ex vivo, has allowed to set up 
important model systems for studying neurogenic processes during development and 
neurobiological mechanisms for maintaining cellular complexity and plasticity. Moreover, 
compelling evidence from transplantation experiments in animal models suggested the 
potential use of NSC lines in novel cell-based therapies for brain injury and 
neurodegenerative disease. Interesting, functional recovery by NSC transplantation was 
mostly reached through alternative mechanisms rather than cell replacement (Pluchino et al. 
2005). These mechanisms include neuroprotection and reduction of host cell death (Chu et 
al. 2004), enhancement of endogenous angiogenesis after stroke (Jiang et al. 2005), 
immunomodulatory effects on inflammatory damage (Pluchino, et al. 2005;Rota Nodari et 
al. 2010;Ziv et al. 2006a) and scavenging of neurotoxic molecules (Emsley et al. 2004).  
Thus far, cells with stem-like properties have been identified in the mammalian CNS, 
including that of humans, throughout development and adulthood (Alvarez-Buylla et al. 
2001;Gage 2000;Temple 2001). In particular, NSCs have been derived from germinative 
zones of the brain such as the hippocampal dentate gyrus, olfactory bulb, subventricular 
zone, subcallosal zone and spinal cord of embryonic, neonatal, and adult rodents (Gritti et 
al. 1996;Reynolds and Weiss 1992;Weiss et al. 1996). The SVZ has the greatest potential for 
neurogenesis and is one of the best characterized niches in the adult brain (Doetsch 2003). It 
consists of a cell layer adjacent to the ependymal layer which lines the lateral ventricles and 
contains three major cell types. The stem-like cells (type B cells ) have an astroglial 
phenotype express the glial-fibrillary acidic protein (GFAP), are slow-proliferating but 
endowed of long-term self-renewal ability (Alvarez-Buylla and Garcia-Verdugo 2002). They 
give rise to transiently amplifying progenitor cells (type C cells) which are typically GFAP- 
and express at meaning levels distal-less homeobox 2 (Dlx2) and Epidermal Growth Factor 
Receptor (EGFR) genes (Pastrana et al. 2009). These type C cells can, in turn, originate 
migrating neuroblasts (type A cells) which acquire the expression of polisyalylated form of 
neural cell adhesion molecule (PSA-NCAM) and of doublecortin (Dcx) and migrate to the 
olfactory bulbs through the a physiological pathway named -rostral migratory stream- 
(RMS). Altogether these cell characteristics suggest that NSCs are the best candidate in 
advanced therapies on neurodegenerative/inflammatory diseases. Indeed in the last decade 
NSC were used to putative treatment in a number of different diseases. 
4. Therapeutic potential of NSC 
4.1 NSCs: Therapy, proof of concept 
Experimentation with intracerebral transplantation of NSCs into animal models has helped 
to individuate strategies to develop pharmacological and cell replacement therapies for 
different neurodegenerative pathologies (Anderson et al. 2001), including both genetic 
diseases like metachromatic leukodystrophy, Huntington’s disease and sporadic 
Alzheimer’s disease (AD), and idiopathic diseases like Parkinson’s disease (PD), multiple 
sclerosis (MS), amyotrophic lateral sclerosis (ALS), and stroke (Kim and de Vellis 2009). 
In particular, Pluchino et al. recently showed that following intravenous or intracerebral 
injection in mice affected by an experimental form of MS (EAE), fetal hNSCs can selectively 
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reach brain and spinal cord areas affected by the demyelinating-inflammatory process and 
contribute to myelin restoration and reduction of astrogliosis in those damaged areas 
(Pluchino et al. 2009;Pluchino et al. 2003). However, a crucial step toward successful clinical 
application of NSC-mediated therapy is to unravel how immunocompetent in vitro 
expanded hNSCs are, whether they are amenable to host rejection following transplantation, 
and whether they present immunomodulatory besides neuroprotective effects after nervous 
system lesions. The major disadvantage of immune suppression is to excessively undermine 
the immunity of the patient and the ensuing enhancement of sensitiveness to multiple 
infections. For a long time a widely held view was that whatever immune activity in the 
brain was detrimental to the neuronal tissue. However recent studies have elucidated a 
neuroprotectant role of immune response on neural repair, which basically relies on the 
mutual interaction between infiltrating blood-immune cells, microglia and neuronal cells, 
namely a cross-play of regenerative signals generated by the “neurovascular niche” (Madri 
2009). Indeed it has been recently shown that both traumatic injury and chronic 
neurodegeneration induce the activation of resident microglia and infiltration of T-cells and 
macrophages from the blood vessels, which can exert evident beneficial besides detrimental 
effects on the surrounding neural tissue (Beers et al. 2006;Glezer et al. 2007;Neumann et al. 
2006;Schwartz and Moalem 2001;Ziv, et al. 2006a;Ziv et al. 2006b). These results in 
combination with unsuccessful clinical studies (in some cases leading to an exacerbation of 
the disease) radically revised the theory of immune suppression as a therapeutic approach 
for neurodegenerative disorders. Moreover, the use of immune suppression in order to 
prevent the rejection of donor NSC transplants can block the immune mediated guidance 
cues required for the “homing” of NSC to the lesion sites (Ben-Hur 2008). In particular, 
Fibroblast Growth Factor 2 (FGF2) (Craig et al. 1996;Kuhn et al. 1997), tumor necrosis factor- 
a (TNF-┙) and Interferon-┛ (IFN-┛) have been shown to induce cell mobilization (Ben-Hur et 
al. 2003), while other cytokines drive NSC migration to the lesion through specific 
physiological pathways, such as the monocyte chemoattractant protein-1 (MCP-1) 
(Belmadani et al. 2006), hepatocyte growth factor (HGF) (Lalive et al. 2005), Epidermal 
Growth Factor (EGF), platelet Growth Factor (PDGF) (Armstrong et al. 1990), and stromal 
derived growth factor (SDF-1 or CXCL12) (Imitola et al. 2004b). 
Interestingly, the majority of hNSC lines expanded in vitro display low dissimilitaries in the 
major histocompatibility complex (MHC) expression pattern, most likely owing to different 
culture conditions and to the origin of the primary tissue. 
The presence of MHC class I and II molecules on human NSC isolated by our group (Figure 
1), or described by Akesson and colleagues (Akesson et al. 2009) would presumably predict 
a risk for rejection after transplantation. However, Akesson demonstrated that neither NSCs 
nor differentiated cells were recognized by alloreactive lymphocytes.. Indeed, human NSCs 
and newly formed astrocytes, but not neurons, suppressed lymphocyte stimulation to 
alloantigens, suggesting low risk for alloreaction and a role as immunomodulators. Despite 
these results, in accordance with providing evidence of NSCs low immunogenicity 
(Odeberg et al. 2005) and ability to produce TGF-┚ cytokine with a potent bystander effect 
on limpho/monocytes (Ubiali et al. 2007), the presence of MHC class I and II molecules on 
hNSCs implies a risk for recognition by alloreactive T cells after transplantation, thus 
indicating a potential risk for immunological rejection due to MHC incompatibility and 
subsequent requirement of immunosuppressive treatment to avoid rejection. 
The disadvantages of using immunosuppressive treatment include an increased risk for 
opportunistic infections, toxic side effects and potential negative effects on donor cells. 
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Notwithstanding several clinical trials harnessing various sources of neural stem cells such 
as ESC-derived progenitors, spinal cord NSC and fetal NSC are currently ongoing 
(www.clinicaltrials.org). 
 
A
 
B
 
Fig. 1. Cytofluorimetric analysis of HLA class I and II on cultured human neural stem cells 
(hNSC). A) absence of HLA DR (Class II) on hNSC cell surface. B) Expression of HLA ABC 
(Class I) on hNSC cell surface 
5. Establishment of human NSC lines for clinical application 
5.1 NSCs: Cells “clinical grade” produced under GMPs guidelines 
Our hNSCs have now been serially expanded under chemically defined conditions and are 
being cryopreserved, establishing a Good Manufacturing Practice (GMP)-grade, hNSCs 
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bank. In order to certify these cells by the GMP standard, a panel of cellular, functional and 
biochemical criteria must be met prior to cell release, which include, but are not limited to, 
karyotype analysis, stable differentiation and growth capacity, and lack of biological 
contamination by adventitious agents.  
In our GMP facility designed to produce human neural stem cells for advanced therapies, 
quality control is only part of overall quality assurance for cell lines which includes: 
evaluation and quality control measures for cells and critical reagents coming into the 
laboratory, control of the laboratory environment, equipment and procedures, control of 
data arising from cell culture, control of the delivery of research materials, including cells, to 
other laboratories and traceability of raw material, especially tissue from donors. 
Four critical characteristics of cell cultures are fundamental to assure the quality of cell 
culture work: 
1. Identity, i.e., the cells need to possess a specific behaviour: 
i. Self Renewal: growth kinetic stable for a elevated number of passages in vitro 
ii. Multipotency: NSCs are able to differentiate into 3 neural lineages (Astrocytes, 
Neuron and oligodendrocytes) after growth factors (EGF and bFGF) removal 
2. Purity, i.e., freedom from microbiological contamination (all the assays need to be 
performed according to official Europeian Pharmacopeia, current edition)  
i. Sterility (Bacteria and fungi) 
ii. Mycoplasma 
iii. Bacterial Endotoxins 
iv. Viral contamination 
v. BSE (at least a risk analysis) 
3. Maintenance of stable functional properties over passaging in vitro 
i. Growth curve: constant positive slope over passages 
ii. Constant ratio neurons/astrocytes/oligodendrocytes upon differentiation assay 
iii. Karyology (healthy karyotype asset and deeper analysis like SKY or comparative 
genomic hybridisation) 
4. Tumorigenicity, i.e., Cell lines not toxic or tumorigenic 
i. Growth factor dependence: the cells died into a few passages after EGF and bFGF 
removal from culture medium. 
ii. No tumor signs after transplantation into the brain of Nude mice (Figure 2). The 
cells are able to migrate, differentiate and integrate into host tissue. 
Because all of the characteristics above mentioned, raw material (media, cell culture plastic 
disposable, etc.) were obtained from GMP certified suppliers. Human Neural Stem Cells 
were produced into controlled environment (class A surrounded by Class B) according to 
Annex I Vol.4 European GMP Guidelines. Tissue samples were obtained from screened 
donors according to European Guidelines on “Certain technical requirements for the 
donation, procurement and testing of human tissues and cell” (Implementing Directive 
2004/23/EC of the European Parliament and of the Council). 
6. Current immunosuppression in transplant 
6.1 Immunosuppressive drugs in cells transplant 
Immunosuppression after transplantations is complex and improved therapeutic strategies 
have contributed to ameliorate the quality of the patient’s life and to enhance the survival of 
the graft; however, the adverse effects associated with immunosuppressive compounds and 
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Fig. 2. Panel A-D) Nude mice were injected in striatum with hNSCs. Six months after 
transplantation mice with hNSCs were sacrificed and immunohistochemistry analysis 
showed that hNSCs engraft efficiently and migrate throughout the injected hemisphere. (A) 
Brain map showing the localization of huN+ cells the cells colonized cortex, cc, striatum, acp 
and mfb. B-D Confocal microscopy analysis showing integration and differentiation of 
hNSC at 6 months from transplantation into the striatum of nude mice. A) migration of gfp- 
Transduced hNSC along the corpus callosum and to the striatum of the ipsilateral 
emisphere. B-D) expression of differentiation and proliferation markers by hNSC identified 
as human-Nuclei (huN)-immunoreactive cells. Immunostaining with the astroglial marker 
Glial Fibrillary Acidic Protein (GFAP, B), the neuronal protein ┚-TubulinIII (C) and the late 
oligodendroglial marker Myelin Basic Protein (MBP, D). Insets show huN+/MBP 
colocalization. Nuclei are shown by dapi staining (blue). Scale bars: in A=100µm; in B-
D=75µm  inset scale bar:  B-D=12-17µm. apc: posterior part of anterior commissure; cc: 
corpus callosum; mfb = medial forebrain bundle 
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DRUG MECHANISM OF ACTION EFFECTS
Cyclosporine Calcineurin inhibitor
Binding to the cytosolic protein cyclophilin of 
immunocompetent lymphocytes and preventing 
the production of IL-2. 
Induction and mainteinance of 
immunosuppression
Tacrolimus (FK-506)
Macrolide antibiotic 
(calcineurin inhibitor)
Reducing peptidyl-prolyl isomerase activity by 
binding to the immunophilin FKBP12 and 
creating a new complex FKBP12-FK506 which 
inhibits both T-lymphocyte signal transduction 
and IL-2 transcription.
Maintenance 
immunosuppression and for 
rescue therapy in patients with 
refractory rejection under 
cyclosporine based therapy
Sirolimus (Rapamycin) Macrolide
Binding the cytosolic protein FK-binding protein 
12 and  inhibiting  the response to IL-2 and the 
activation of T and B-cells.
Maintenance 
immunosuppression and 
protection from chronic 
rejection 
Mycophenolate mofetil 
(MMF)
Prodrug of Mycophenolic 
Acid
Inhibiting inosine monophoshate 
dehydrogenase impairing B and T-cells 
proliferation.
Maintenance 
immunosuppression and 
protection from chronic 
rejection 
Azathiopine Purine analogue
Decreasing DNA and RNA synthesis and 
inhibiting the proliferation of fast-growing 
lymphocytes (T and B-cells particulary)
Maintenance 
immunosuppression 
Corticosteroids Steroids hormones
Preventing interleukin IL-1 and IL-6 production 
by macrophages and inhibiting all stages of T-
cells activation
Induction, maintenance 
immunosuppression and 
protection from acute rejections
Muromonab-CD3 (OKT-3)
Monoclonal Antibody of 
IgG2A  clones  to the CD3 
portion of the T-cell 
recepto  Blocking T-cell function 
Induction of 
immunosuppression and 
protection from acute rejection 
(primary treatment or steroid-
resistant)
w
w
w
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the risks of inducing a long-term immunosuppression represent a challenging issue for 
researches and clinicians. Total body radiation after organs’ transplantation was among the 
first protocols of immunosuppression, but it resulted as extremely severe and led inexorably 
to the death of all the patients. Therefore, steroid alone were used without success. With the 
development of 6-mercaptopurine (Purinethol), followed by azathioprine (Imuran) in the 
1960s, pharmacological immunosuppression became the standard protocol after both organs 
and cells transplantation until 1980s, when cyclosporine (Sandimmune and Neoral) was 
introduced as the first calcineurin inhibitor. Calcineurin is a protein phosphatase also 
known as protein phosphatase 3, PPP3CA, which activates the T cells of the immune system 
and can be blocked by drugs. Cyclosporine was initially used in combination with 
azathioprine and steroids and was credited with a dramatic improvement of graft survival. 
Cyclosporin is thought to bind to the cytosolic protein cyclophilin (an immunophilin) of 
immunocompetent lymphocytes, especially T-lymphocytes. This complex of ciclosporin and 
cyclophilin inhibits the phosphatase calcineurin, which under baseline conditions induces 
the transcription of interleukin-2. The drugs also inhibits lymphokine production and 
interleukin release, leading to a reduced function of effector T-cells. In 1994 another 
calcineurin inhibitor, the macrolide antibiotic Tacrolimus (or FK-506), active against helper T 
cells, became available and gradually supplanted cyclosporine in many clinical Institutes. It 
has been largely used for maintenance of the immunosuppression and for rescue therapy in 
patients with refractory rejection under cyclosporine-based therapy. However, the risk of 
both acute and chronic nephrotoxicity attributed to calcineurin inhibitors has strongly 
suggested the development of protocols free of these agents as most desirable. 
At the present, numerous immunosuppressive drugs and protocols have been designed for 
transplantation (Table 1), but a protocol which is highly effective with minimal side effects 
has still to be identified. In this view, although the brain is commonly considered partially 
“immunoprivileged”, a specific immunosuppression regimen has to provide the best 
conditions allowing graft survival, preventing the patient from the additional burden of an 
immune reaction against the graft (Barker and Widner 2004).  
Actually, the precise sequelae of events leading from antigen recognition to lymphocyte 
activation and  proliferation has still to be elucidated. However, recent findings, concerning 
the molecular actions of cyclosporine A (CsA) and the new immunosuppressive drugs, 
Tacrolimus and Rapamycin, have provided important novel breakthroughs in the 
biochemical processes involved. Interestingly, none of the T-cell directed 
immunosuppressants is, by itself, anti-lymphocyitic. Conversely, these molecules act as 
“molecular adaptors” which mediate the interaction between specific intracellular drug-
binding proteins and target molecules. Several additional drugs are currently used as 
immunomodulatory agents, eventually in combination with Calcinneurin inhibitors. Most of 
these, like steroids, azathioprine, MMF, sirolimus, are routinely used in peripheral organ 
allograft programs with a unique and different mode of action to that of tacrolimus and 
cyclosporin A (Table1). The use of adjuvants agents allows clinicians to achieve adequate 
immunosuppression while decreasing the dose and the toxicity of individual agents. 
In neural transplantation, immunomodulators have been used experimentally, in particular 
with xenografts. Antibodies against T-cell receptor anti-TCR and T cells have been used to 
enhance the survival of intracerebral neural xenografts in rats (Okura et al. 1997;Wood et al. 
1996). Also the use of blockers of T-cells costimulatory molecules have been explored as 
alternative route to tolerance, therefore highlighting the value of targeting this arm of the 
immune response for xenograft survival (Larsson et al. 2003;Larsson et al. 2002). 
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7. Low immunogenic potential of NSC 
We already obtained some evidence of hNSCs efficacy and immunogenic tolerance upon 
transplantation into animal models of neurological disorders (Rota Nodari, et al. 2010) such 
as transient global ischemia, which is a model of vascular dementia and resembles several 
pathological features of AD. At 3 days from global ischemic injury, hNSC were unilaterally 
implantated into the corpus callosum or the hippocampal fissure of adult rat brains. After 1 
month, hNSCs were detected to migrate through the corpus callosum (Fig.3), into the cortex 
or throughout the dentate gyrus of the hippocampus and by the fourth month, to reach the 
ipsilateral subventricular zone, the CA1-3 hippocampal layers and the controlateral 
hemisphere, showing to be non-tumorigenic and to undergo a proper regional 
differentiation into GABAergic and GLUTAmatergic neurons (Rota Nodari, et al. 2010). 
Notably, these results could be accomplished using transient immunosuppression, i.e 
administering cyclosporine for 15 days following the ischemic event. A wide array of 
studies have shown that NSCs are not susceptible to immunological rejection (Bjorklund et 
al. 2003;Mendez et al. 2008;Olstorn et al. 2007;Wennersten et al. 2006) even when 
transplanted in animal models like EAE, characterized by a constitutively activated 
immunological response(Pluchino, et al. 2003;Pluchino, et al. 2005). Similar results were also 
obtained in a different context: after transplantation into the adult rat brain lesioned by focal 
demyelination (Ferrari et al., submitted), hNSCs demonstrated to integrate into the NSC 
host niche and to migrate toward the lesioned corpus callosum, where they properly 
differentiated into myelinating oligodendrocytes. No sign of tumorigenicity was ever 
 
 
Fig. 3. hNSC transduced with a lentiviral vector carrying the reporter gene gfp were 
transplanted into the brain of adult rats after 3 days from lesioning by transient global 
ischemia. Confocal microscopy analysis showing hNSC-GFP integration into the corpus 
callosum (A) (1 month from transplantation) and in the hippocampal CA3 layer (B) ( 4 
months from transplantation) under transient immunosuppression. Total nuclei are shown 
by dapi staining (blue). Scale Bar: 50µm. cc: corpus callosum; CA3: hippocampal layer 
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detected upon transplantation of hNSCs (unpublished observation) nor of hNSC 
immortalized with proliferating genes as c-myc, c-myc T58A and v-myc (De Filippis et al. 
2008; De Filippis et al. 2007). These results have confirmed that hNSC are scarcely 
immunogenic. Consistently, parallel analysis of hNSC in vitro by cytofluorimetric assays 
showed that hNSC display only a very faint expression of HLA DR compared to a normal 
expression of HLA A, B and C (see Figure 1). Moreover, recent studies have shown that 
hNSCs may also exert their therapeutic potential through an immunomodulatory action 
(Bacigaluppi, et al. 2009; Pluchino, et al. 2009; Pluchino, et al. 2005). 
8. NSC-mediated immunomodulation of the inflammatory component in 
neurodegenerative disorders 
Besides neurodegeneration per se, one of the hallmarks characterizing most neurodegenerative 
disorders like stroke, AD, PD, ALS, MLD, is the development of an inflammatory 
environment, which can contribute to tissue damage (Glass et al. 2010). Although for a long 
time the NSC-mediated therapy was basically aimed at replacing damaged neural cells 
(Lindvall et al. 2004; Pluchino, et al. 2003), the local immune response has been shown to play 
a key role in recruitment of neural precursors to the lesion site. When neuroinflammation is 
prevailing over neurodegeneration, NSC have been shown to promote long-lasting 
neuroprotection and to exert unexpected immune-like functions (Pluchino, et al. 2005). 
Pluchino et al. (Pluchino, et al. 2005) showed that after systemic injection into a mouse 
model of multiple sclerosis, transplanted NSC are recruited into perivascular niche areas, 
where they retain undifferentiated features, proliferate and promote CNS repair through a 
cross-talk with inflammatory CNS-infiltrating T cells. A dual role in the regulation of both 
neurogenesis and oligodendrogenesis of adult neural progenitor cells is played by microglia 
(Streit 2002), so that the two physiological processes can be blocked by inflammation-
associated microglia or induced by IL-4/IFN-γ associated to T-helper cells (Butovsky et al. 
2006). Several studies have demonstrated that T cells able to recognize CNS antigens can foster 
spontaneous recovery from CNS injuries through an active cross-talk with local microglia 
(Hauben et al. 2000;Hofstetter et al. 2003;Moalem et al. 1999;Yoles et al. 2001). Consistently, T 
cell-based vaccination of mice with a myelin-derived peptide appeared to synergistically 
promote functional recovery after spinal cord injury when combined with transplantation of 
neural precursors into the cerebro-spinal fluid (Ziv, et al. 2006a). It’s important to consider that 
immune cells are involved in the control of neurogenesis even under physiological conditions 
(Ziv, et al. 2006b). However, under pathological environment, the outcome of the interplay 
between inflammation, synaptic transmission and neurodegeneration is strongly conditioned 
by the short- or long-term persistence of inflammation (Centonze et al. 2010;Pluchino et al. 
2008). Upon acute inflammatory injuries, such as stroke, neurogenesis is notably increased 
(Zhang et al. 2004). Conversely, a persistent brain inflammation in chronic inflammatory 
disorders, such as MS (Pluchino, et al. 2008) has been shown to alter both the proliferative and 
migratory capacities of NSCs in the SVZ, thus leading to a perpetuating non cell-autonomous 
dysfunction of the endogenous CNS stem cell compartment. 
Both in the globally ischemic and focally demyelinated rat brains, we observed that 
transplantation of hNSCs can effectively decrease reactive astrogliosis and dampen 
microglial activation in the injuried areas (Rota Nodari, et al. 2010); unpublished results). 
This phenomenon may, in fact, participate in the low immunogenic response that these cells 
seem to elicit in the CNS, together with the lack of expression of Molecular 
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Histocompatibility Complex class II components (MHCII) (Imitola et al. 2004a;Imitola, et al. 
2004b)(see also Fig 1). Notwithstanding, it is also true that some level of immune 
surveillance is maintained in the adult brain upon NSC engraftment, which explains the 
widespread need to use immune suppression (Wennersten, et al. 2006) in experimental and 
clinical intracerebral transplantation (Bjorklund, et al. 2003;Olstorn, et al. 2007).The 
successful use of transient immunosuppression proposes a suitable milder approach to 
immunosuppression for the prospective use of hNSCs for clinical purposes. The fact that the 
discontinuous treatment with cyclosporine does not affect integration of transplanted cells 
in most of the brain regions, which to all effects emerge as immunoprivileged when 
considering hNSCs, is in good accordance with most recent findings (Wennersten, et al. 
2006). These evidences are driving the progressive translation of the knowledge “from the 
bench to the bedside”, thus leading to the use of hNSCs as a suitable tool to model 
transplantation in pre-clinical settings and to the promotion of GMP-grade hNSC for stem 
cell-mediated therapy of neurodegenerative disorders.  
9. Transplanted NSC switch on or off the immune reactivity into host?  
Usually, after the cell or tissue transplant into CNS, the intensity and rapidity of the 
rejection depend on the phylogenetic distance between donor and host (Dymecki et al. 
1990;Mason et al. 1986;Pakzaban and Isacson 1994) and the status of the host immune 
system (Marion et al. 1990), but also from the nature and differentiation state of transplanted 
cells. Capetian and colleagues (Capetian et al. 2011) demonstrate that murine NSCs derived 
from newborn C57BL/6,  cultured as neurospheres and placed into kidney capsule as a non-
immunopriviliged site of BALB/c survived  for 28 days without rejection although these 2 
strains were been immunologically incompatible. However the graft were readly rejected 
when the recipient animal was either pre or post sensitized using donor splenocytes. 
Also in these example, as well as in our human cells (Figure 1) the murine neural stem cells 
showed no expression of MHC I or II, in contrast with surrounding tissue or other 
terminally differentiated cells. This demonstrated that NSCs themselves are not attacked by 
immune defense mechanisms since they do not sensitize host (so they have a low 
immunogenicity), but can however be rejected if the host is or becomes sensitized. 
In the past there have been concerns that the loss or lack of clinical improvement after 
neural grafting could be due to immunological rejection processes that compromise neural 
graft survival and function. However, autopsy findings of patients at long-term follow-up 
post-transplantation showed little evidence of immunological reactions (Freeman et al. 
2000;Kordower et al. 2008;Kordower et al. 1996;Li et al. 2008;Mendez et al. 2005). 
According to results of different clinical trials on Huntington Disease where all the patients 
received adequate immunosuppression for over 1 year, most of the patients developed anti 
HLA I antibodies but only few showed overt signs of immunological rejection. 
Moreover there are accruing evidences (Pluchino, et al. 2009) that NSCs injected into CNS or 
intravenously in multiple sclerosis animal models are scarcely (if any) prone to differentiate, 
while they are able to exert a plethora of “healing actions”, such as production of pleiotropic 
factors and cytokines, scavenging of toxic molecules and immunomodulation of the 
inflammatory environment. In addition Akesson and colleagues (Akesson, et al. 2009) have 
shown that human Neural stem cells derived from aborted fetuses of 5-12 weeks of 
gestation  were able to inhibit lymphocyte proliferation induced by alloantigen and at 
NSC:Lymphomonocyte ratio of 1:1 a complete suppression was seen. These effect was 
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clearly specific and mediated by cell-cell interactions as demonstrated by tha fact that the 
above mentioned proliferation was not affected by presence or absence of supernatants from 
NSCs cultures. 
Moreover, recent evidence has suggested that the majority of the stem cell-mediated 
therapeutic effects in inflammatory CNS disorders are possibly taking place peripherally, at 
the level of immune relevant anatomical site, such as secondary lymphoid organs. 
On the other hand the surgery could influence “per se” the fate of transplanted cells, albeit 
stereotactic techniques allow to inject NSCs by a minimally invasive procedure. 
There are three main factors to be taken in account that can influence the extent of the host 
reaction and graft survival in an intraparenchimal cell graft: i) the extent of tissue trauma 
during injection, ii) cell suspension preparation and iii) the site of implantation. 
The intraparenchymal injection lead to breakage of blood brain barrier at least for a couple 
of weeks facilitating the limphomonocyte patrolling and reaction against the graft. A low 
viability of cell suspensions could also trigger an immune reaction. Furthermore, the site of 
implantation can have a considerable effect on the host immune reaction. For example, peri- 
or intraventricular graft placement can lead to increased rates of immune response in terms 
of MHC class I expression inside the grafts and lymphocyte invasion (Oertel et al. 2004). 
10. Conclusions 
Although NSCs cell therapy seem to be a promising development for a number on 
neurological diseases, transplantation of NSC into the central nervous system is from an 
immunological viewpoint a true challenge both for the host as well as for the donor cells. 
Moreover more experiments are necessary to fully elucidate the mechanisms underlining 
the interactions between stem cells graft and host immune system. In conclusion, the mildest 
approach for clinical trials on humans is likely a transient immunosuppression regimen. 
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